Tamiflu® (oseltamivir phosphate) oral suspension – First-time generic

- On September 14, 2017, the FDA approved Nesher Pharmaceuticals' AB-rated generic version of Genetech's Tamiflu (oseltamivir phosphate) oral suspension.

- Tamiflu is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients ≥ 2 weeks of age who have been symptomatic for no more than 48 hours and for the prophylaxis of influenza A and B in patients ≥ 1 year of age.

    - Tamiflu is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices.
    - Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Tamiflu.
    - Tamiflu is not recommended for patients with end-stage renal disease not undergoing dialysis.

- Tamiflu is also available generically as oral capsules.

- Nesher Pharmaceuticals' launch plans for generic Tamiflu oral suspension are pending.